Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
- Resource Type
- Abstract
- Source
- In
Gynecologic Oncology April 2015 137 Supplement 1:144-144 - Subject
- Language
- ISSN
- 0090-8258